ClinicalTrials.gg
CompletedNCT04605549Updated Mar 3, 2026Results posted

A Study of CIN-107 in Adults With Primary Aldosteronism

A Phase 2 interventional study of CIN-107 2 mg dosing and CIN-107 4 mg dosing in Primary Aldosteronism and Hyperaldosteronism, sponsored by AstraZeneca. Completed at 10 sites in United States. Open to participants aged 18 Years to 130 Years. Per ClinicalTrials.gov, last updated 2026-03-03.

Sponsored by AstraZeneca · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
15
Allocation
Not applicable
Ages
18 Years to 130 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 19 studies in Hyperaldosteronism with a site in United States — 4 open to participants now, 7 under way, 1 of them phase 3. Hyperaldosteronism · United States.

Started
2021
the only one that year
Phase 2
4 of 19
1 open now
Registered
12th of 19
by date
Lead sponsor
2 of 19
AstraZeneca

Among the 19 studies in Hyperaldosteronism with a site in United States, this one is the only one that started in 2021, is one of 4 in phase 2, and was the 12th registered.

Hyperaldosteronism

201 studies on the registry are indexed under Hyperaldosteronism; 91 are open to participants now.

Browse Hyperaldosteronism studies →

Open to participants now

4 of the 19 studies in Hyperaldosteronism with a site in United States are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 68 Hyperaldosteronism studies recruiting now, 22 (32%) set no upper age limit and 30 (44%) stop at 75 or younger; 6 take children under 18; 14 take healthy volunteers.

This study: 18 Years to 130 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies in Hyperaldosteronism with a site in United States, or all of them as a file.
02

Study summary

This is a multicenter, open-label study in adult patients with PA to evaluate the effectiveness and safety of CIN-107 after up to 12 weeks of treatment (Part 1), and then for eligible, consenting patients follow patients in Part 2 for up to 74 weeks for evidence of long-term safety and tolerability.

Read the detailed description

For patients in Part 1 only :

The treatment duration for patients who complete all 3 dose levels, and who opt not to continue in the extension part of the study, is 12 weeks. For patients who do not complete up-titration, the treatment duration will include at least 4 weeks of dosing with the final dose level. If down-titration of CIN-107 dose is determined at Visit 6 (Week 9), the total treatment duration may be extended to 13 weeks to allow sufficient time for CIN-107 treatment effect at the final dose to be assessed. If the final dose of CIN-107 is reached before week 8 (Visit 5) and no up-titration occurs at Visit 5, the patients will be encouraged to continue CIN-107 treatment till Visit 7 for a total of 12 weeks of treatment. The patients who opt not to continue to Part 2 will not receive any study drug and will return for their safety follow up visit (Visit 8) in 2 weeks.

For patients who opt to continue in the extension part (Part 2) of the study:

Patients will continue to receive their dose of baxdrostat and be instructed to measure BP at least once every week prior to dosing with CIN-107 in the morning, during the extension phase. Safety surveillance will be conducted if clinically indicated. Repeat and unscheduled testing for serum potassium may be measured at the investigator's clinical site or at local laboratory for a faster turn-around time to allow clinical assessment. These patients entering part 2 will skip Visit 8 and their next visit will be Visit 9.

03

Conditions studied

  • Primary Aldosteronism
  • Hyperaldosteronism

Browse trials for

Keywords

  • Primary Aldosteronism
04

Who can participate

Ages eligible
18 Years to 130 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Have been diagnosed with PA.
  2. Are taking mineralocorticoid receptor antagonist (MRA) to control BP; or are newly diagnosed with PA and have not started MRA treatment.
  3. Are willing and able to cease dosing of MRA for up to 4 weeks in patients taking MRA.
  4. Are willing to be compliant with the and reproduction restrictions of the study.
  5. Have increased SBP by ≥ 20 mmHg or have SBP ≥ 160 mmHg after dosing of MRA treatment is ceased for up to 4 weeks duration, or have SBP ≥ 150 mmHg for patients who are newly diagnosed with PA and have not taken an MRA in the past 12 weeks.

Exclusion criteria

Exclusion Criteria:

  1. At Screening Visit, have a single occurrence of mean seated SBP > 180 mmHg or DBP > 110 mmHg if not taking an MRA; or have a mean seated SBP ≥ 160 mmHg or DBP ≥ 100 mmHg if currently taking an MRA.
  2. Have a > 45 kg/m2.
  3. Have had a previous surgical intervention for an adrenal adenoma or have a planned adrenal carcinoma, adrenalectomy, renal nerve denervation, or adrenal ablative procedure during the course of the study.
  4. Have a documented estimated \< 45 mL/min/1.73 m2.
  5. Have a planned dialysis, kidney transplantation or any major surgical procedure during the course of the study.
  6. Have known documented class III or IV chronic heart failure.
  7. Have had a stroke, , hypertensive encephalopathy, acute coronary syndrome, or hospitalization for heart failure within 6 months before the Screening Visit.
  8. Have known current severe left ventricular outflow obstruction.
  9. Have had major cardiac surgery within 6 months before the Screening Visit.
  10. Have a history of, or currently experiencing, arrhythmias.
  11. Have had a prior solid organ transplant or cell transplant.
  12. Are positive for antibody, virus RNA, or surface antigen.
  13. Have typical consumption of > 14 alcoholic drinks weekly.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
15 participants (actual)

Study arms

  • Experimental
    CIN-107 for dosing at 2, 4, or 8 mg (QD)

    Patients will be provided with an initial dose of CIN-107 and start once daily (QD) dosing of CIN-107 tablets at 2 mg. At Visit 4, CIN-107 dose may be up-titrated to 4 mg QD if the patient has tolerated dosing of CIN-107 at 2 mg and the blood pressure (BP) records indicate minimal hypotension risk. At Visit 5, CIN-107 dose may be up-titrated to 8 mg QD if the patient has tolerated dosing of CIN-107 at 4 mg.

    Drug: CIN-107 2 mg dosing · Drug: CIN-107 4 mg dosing · Drug: CIN-107 8 mg dosing

Interventions

  • One tablet of CIN-107 2 mg tablets, once daily, by mouth, for dosing at 2 mg.

  • Two tablets of CIN-107 2 mg tablets, once daily, by mouth, for dosing at 4 mg.

  • Four tablets of CIN-107 2 mg tablets, once daily, by mouth, for dosing at 8 mg.

06

What researchers measure

Primary outcomes

  1. Number of Treatment Emergent Adverse Events

    An AE is defined as any untoward medical occurrence in a clinical investigation that occurs to a patient administered a pharmaceutical product, which does not necessarily have a causal relationship with this treatment. Adverse events were collected from the beginning of the study until Week 74. Treatment emergent AEs are defined as AEs that newly occur or worsen in severity during the treatment period.

    Time frame: 74 weeks

  2. Change From Baseline in Mean Seated Systolic Blood Pressure (SBP) in Patients With Primary Aldosteronism

    The mean seated SBP was defined as the average of 3 measurements obtained at the clinical site visit. The change from baseline in mean seated SBP after 12 weeks of treatment with CIN-107 (Part 1) is calculated.

    Time frame: 12 weeks

Secondary outcomes

  1. Change From Baseline in Mean Diastolic Blood Pressure (DBP) in Patients With Primary Aldosteronism

    The mean DBP was defined as the average of 3 measurements obtained at the clinical site visit. The change from baseline in mean DBP after 12 weeks of treatment with CIN-107 (Part 1) is calculated.

    Time frame: 12 weeks

  2. The Percentage of Patients Achieving a Seated BP Response of <140/90 mmHg

    The percentage of patients achieving a mean seated SBP \<140 mmHg and a mean DBP of \<90 mmHg after 12 weeks of treatment with CIN-107 (Part 1) is calculated.

    Time frame: 12 weeks

  3. The Percentage of Patients Achieving a Seated BP Response of <130/80 mmHg

    The percentage of patients achieving a mean seated SBP \<130 mmHg and a mean DBP of \<80 mmHg after 12 weeks of treatment with CIN-107 (Part 1) is calculated.

    Time frame: 12 weeks

  4. The Percentage of Patients Achieving the Pharmacodynamic Marker Response

    Pharmacodynamic marker response is defined as achieving either: - a plasma aldosterone concentration (PAC) \< 15 ng/dL and a plasma renin activity (PRA) ≥ 0.5 ng/mL/h; or - an ARR \< 15; or - unsuppressed renin activity PRA ≥ 1.0 ng/mL/h

    Time frame: 12 weeks

07

Results

Posted Mar 3, 2026

Participant flow

The study was conducted from 08 March 2021 to 28 October 2024 at 10 sites in United States

Part 1 (0 to 12 Weeks)
Participant flow — Part 1 (0 to 12 Weeks)
MilestoneCIN-107
Started15
Completed15
Not completed0
Part 2 (12 to 74 Weeks)
Participant flow — Part 2 (12 to 74 Weeks)
MilestoneCIN-107
Started14
Completed12
Not completed2
Withdrew: Adverse event1
Withdrew: Lost to follow-up1

Outcome measures

PrimaryNumber of Treatment Emergent Adverse Events

An AE is defined as any untoward medical occurrence in a clinical investigation that occurs to a patient administered a pharmaceutical product, which does not necessarily have a causal relationship with this treatment. Adverse events were collected from the beginning of the study until Week 74. Treatment emergent AEs are defined as AEs that newly occur or worsen in severity during the treatment period.

Time frame:
74 weeks
Reported as:
Number · Number of events
Number of Treatment Emergent Adverse Events
Number of eventsCIN-107
Part 1 before titration (0-Week 4)27
Part 1 after titration (Week 4-Week 12)34
Part 2 (Week 12-Week 74)101
PrimaryChange From Baseline in Mean Seated Systolic Blood Pressure (SBP) in Patients With Primary Aldosteronism

The mean seated SBP was defined as the average of 3 measurements obtained at the clinical site visit. The change from baseline in mean seated SBP after 12 weeks of treatment with CIN-107 (Part 1) is calculated.

Time frame:
12 weeks
Reported as:
Mean · mmHg
Change From Baseline in Mean Seated Systolic Blood Pressure (SBP) in Patients With Primary Aldosteronism
mmHgCIN-107
Change From Baseline in Mean Seated Systolic Blood Pressure (SBP) in Patients With Primary Aldosteronism-24.9 ± 11.6
SecondaryChange From Baseline in Mean Diastolic Blood Pressure (DBP) in Patients With Primary Aldosteronism

The mean DBP was defined as the average of 3 measurements obtained at the clinical site visit. The change from baseline in mean DBP after 12 weeks of treatment with CIN-107 (Part 1) is calculated.

Time frame:
12 weeks
Reported as:
Mean · mmHg
Change From Baseline in Mean Diastolic Blood Pressure (DBP) in Patients With Primary Aldosteronism
mmHgCIN-107
Change From Baseline in Mean Diastolic Blood Pressure (DBP) in Patients With Primary Aldosteronism-10.6 ± 8.95
SecondaryThe Percentage of Patients Achieving a Seated BP Response of <140/90 mmHg

The percentage of patients achieving a mean seated SBP \<140 mmHg and a mean DBP of \<90 mmHg after 12 weeks of treatment with CIN-107 (Part 1) is calculated.

Time frame:
12 weeks
Reported as:
Count of participants · Participants
The Percentage of Patients Achieving a Seated BP Response of <140/90 mmHg
ParticipantsCIN-107
The Percentage of Patients Achieving a Seated BP Response of <140/90 mmHg11
SecondaryThe Percentage of Patients Achieving a Seated BP Response of <130/80 mmHg

The percentage of patients achieving a mean seated SBP \<130 mmHg and a mean DBP of \<80 mmHg after 12 weeks of treatment with CIN-107 (Part 1) is calculated.

Time frame:
12 weeks
Reported as:
Count of participants · Participants
The Percentage of Patients Achieving a Seated BP Response of <130/80 mmHg
ParticipantsCIN-107
The Percentage of Patients Achieving a Seated BP Response of <130/80 mmHg6
SecondaryThe Percentage of Patients Achieving the Pharmacodynamic Marker Response

Pharmacodynamic marker response is defined as achieving either: - a plasma aldosterone concentration (PAC) \< 15 ng/dL and a plasma renin activity (PRA) ≥ 0.5 ng/mL/h; or - an ARR \< 15; or - unsuppressed renin activity PRA ≥ 1.0 ng/mL/h

Time frame:
12 weeks
Reported as:
Count of participants · Participants
The Percentage of Patients Achieving the Pharmacodynamic Marker Response
ParticipantsCIN-107
The Percentage of Patients Achieving the Pharmacodynamic Marker Response12

Adverse events

Collected over From first dose of study drug to the end of the study at week 74. Note that the study was divided in 2 parts: Part 1 starting at the date of first dose and ending at Week 12 with an additional safety follow-up at Week 14 for those opting out of part 2 while Part 2 starts at Week 12 and ends at Week 72 with an additional safety follow-up at Week 74.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
CIN-107 2 mg Part 1 - Before Titration0/15 (0%)0/15 (0%)11/15 (73.3%)
CIN-107 2 mg Part 1 - After Titration0/3 (0%)0/3 (0%)1/3 (33.3%)
CIN-107 4 mg Part 1 - After Titration0/13 (0%)0/13 (0%)8/13 (61.5%)
CIN-107 8 mg Part 1 - After Titration0/8 (0%)0/8 (0%)2/8 (25%)
CIN-107 2 mg Part 20/4 (0%)0/4 (0%)4/4 (100%)
CIN-107 4 mg Part 20/7 (0%)0/7 (0%)6/7 (85.7%)
CIN-107 8 mg Part 20/7 (0%)1/7 (14.3%)7/7 (100%)
Most frequent serious events
Most frequent serious events
EventCIN-107 2 mg Part 1 - Before TitrationCIN-107 2 mg Part 1 - After TitrationCIN-107 4 mg Part 1 - After TitrationCIN-107 8 mg Part 1 - After TitrationCIN-107 2 mg Part 2CIN-107 4 mg Part 2CIN-107 8 mg Part 2
HyperkalaemiaMetabolism and nutrition disorders0/150/30/130/80/40/71/7
Most frequent other events
Showing 10 of 96
Most frequent other events
EventCIN-107 2 mg Part 1 - Before TitrationCIN-107 2 mg Part 1 - After TitrationCIN-107 4 mg Part 1 - After TitrationCIN-107 8 mg Part 1 - After TitrationCIN-107 2 mg Part 2CIN-107 4 mg Part 2CIN-107 8 mg Part 2
PalpitationsCardiac disorders0/150/31/130/82/40/70/7
Blood creatinine increasedInvestigations0/150/30/130/82/40/71/7
HyperkalaemiaMetabolism and nutrition disorders0/150/31/130/82/43/71/7
Asymptomatic bacteriuriaInfections and infestations0/151/30/130/80/40/70/7
ProteinuriaRenal and urinary disorders0/151/30/130/80/40/70/7
CoughRespiratory, thoracic and mediastinal disorders0/151/30/130/81/41/70/7
Oedema peripheralGeneral disorders0/150/30/130/80/40/72/7
Covid-19Infections and infestations0/150/31/130/81/40/72/7
HeadacheNervous system disorders4/150/32/130/80/42/70/7
Acute kidney injuryRenal and urinary disorders0/150/30/130/81/40/72/7

Baseline characteristics

ITT Population defined as all participants enrolled in the study. Due to the small sample size of the study, arms/groups are combined for analysis.

Age, Continuous
Age, Continuous(Years)CIN-107
Mean53.6 ± 11.6
Sex: Female, Male
Sex: Female, Male(Participants)CIN-107
Female5
Male10
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)CIN-107
WHITE7
BLACK OR AFRICAN AMERICAN4
ASIAN3
Other1
Region of Enrollment
Region of Enrollment(Participants)CIN-107
USA15
Seated SBP
Seated SBP(mmHg)CIN-107
Mean151.5 ± 13.46
08

Study locations

10 sites
  • Research Site
    Greenbrae, California 94904, United States
  • Research Site
    San Francisco, California 94110, United States
  • Research Site
    West Hollywood, California 90048, United States
  • Research Site
    Chicago, Illinois 60611, United States
  • Research Site
    Baltimore, Maryland 21287, United States
  • Research Site
    Ann Arbor, Michigan 48109, United States
  • Research Site
    Rochester, Minnesota 55905, United States
  • Research Site
    Cincinnati, Ohio 45245, United States
  • Research Site
    Columbus, Ohio 43210, United States
  • Research Site
    Dallas, Texas 75390-9047, United States
09

References and documents

Publications

  • Townsend RR. Blocking Aldosterone Synthesis: Whose BrigHTN Idea Was That? Clin J Am Soc Nephrol. 2023 Dec 1;18(12):1631-1633. doi: 10.2215/CJN.0000000000000265. Epub 2023 Jul 24. No abstract available. PubMed 37490693 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. "Yes", indicates that AZ are accepting requests for IPD, but this does not mean all requests will be approved.

Supporting information: Study protocol, Statistical analysis plan

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA/PhRMA Data-Sharing Principles. For details of our timelines, please refer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. A Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2021 to primary completion in Oct 2024, 43 months.

Results were first posted in Mar 2026, 1 year 4 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 22, 2020
First posted
Oct 28, 2020
StartActual
Mar 8, 2021
Primary completionActual
Oct 28, 2024
CompletionActual
Oct 28, 2024
Results first posted
Mar 3, 2026
Last update
Mar 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 3, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04605549
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Oct 28, 2020
Start date
Mar 8, 2021
Primary completion
Oct 28, 2024
Completion
Oct 28, 2024
Results posted
Mar 3, 2026
Last update
Mar 3, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Baxdrostat

Start the discussion